Related Experiment Video

Updated: Mar 28, 2026

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

723

Potential Drug Combinations to Reduce Cardiovascular Disease Burden in Diabetes

Sivaram Pillarisetti1

  • 1Kareus Therapeutics SA, La Chaux-de-Fonds, Switzerland; NeuroPn Therapeutics, GA, Alpharetta, USA.

Trends in Pharmacological Sciences
|January 1, 2016
PubMed

Insights

Cardiovascular disease (CVD) is a major threat for type 2 diabetes (T2DM) patients. This review explores effective drug combinations to manage postprandial glucose and triglycerides, aiming to reduce CVD risk in T2DM.

Area of Science:

  • Endocrinology
  • Cardiology
  • Pharmacology

Background:

  • Cardiovascular disease (CVD) is the leading cause of mortality and morbidity in type 2 diabetes mellitus (T2DM).
  • Intensive glucose control has shown limited success in reducing cardiovascular events, and standard dyslipidemia treatments offer insufficient protection.
  • Postprandial glucose and triglyceride levels are significant predictors of myocardial infarction and mortality in T2DM patients.

Purpose of the Study:

  • To review current therapeutic strategies for managing postprandial hyperglycemia and hypertriglyceridemia in T2DM.
  • To identify effective drug combinations for reducing cardiovascular risk in T2DM patients.
  • To discuss the potential benefits of specific drug combinations on postprandial glucose and triglyceride levels.

Main Methods:

  • Review of recent clinical trials and studies on T2DM, CVD, and glucose/lipid metabolism.
  • Analysis of data linking postprandial glucose and triglyceride levels to cardiovascular outcomes.
  • Discussion of pharmacological approaches targeting postprandial dysregulation.

Main Results:

  • Current strategies for reducing postprandial hyperglycemia and lipemia have not effectively lowered the CVD burden.
  • Postprandial glucose and triglyceride levels are strong predictors of myocardial infarction and mortality.
  • Combinations of existing drugs may offer a preferred approach to reduce postprandial glucose and triglycerides.

Conclusions:

  • Managing postprandial glucose and triglyceride excursions is crucial for mitigating CVD risk in T2DM.
  • Novel therapeutic strategies focusing on postprandial control are needed.
  • Combinations of currently available drugs show promise for improving cardiovascular outcomes in T2DM by targeting postprandial glucose and TG.

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
520
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.6K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
578
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
922
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K